GNMK - GenMark Diagnostics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

GenMark Diagnostics, Inc.

5964 La Place Court
Carlsbad, CA 92008
United States

IndustryMedical Devices
Full Time Employees477

Key Executives

NameTitlePayExercisedYear Born
Mr. Hany MassaranyCEO, Pres & Director1MN/A1961
Mr. Scott MendelChief Operating Officer530.88kN/A1967
Mr. James B. McNallySr. VP of Marketing & Bus. Devel.414.03kN/A1980
Mr. Michael GleesonSr. VP of Corp. & Strategic Accounts403.76kN/A1975
Mr. Brian Andrew MitchellSr. VP of Operations381.51kN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Corporate Governance

GenMark Diagnostics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.